Oral Antiviral Therapy Utilization Among Adults with Recent COVID-19 in the United States.
Oral Antiviral Therapy Utilization Among Adults with Recent COVID-19 in the United States.
复制标题
DOI：
10.1007/s11606-023-08106-6
复制
发表时间：
2023-05
影响因子：
5.7
通讯作者：
Geller, Alan C.
中科院分区：
文献类型：
--
作者：
Benchimol-Elkaim, Brandon;Dryden-Peterson, Scott;Miller, Donald R.;Koh, Howard K.;Geller, Alan C.
据我们所知，这是第一项评估美国COVID-19口服抗病毒治疗（OAV）摄入情况并评估其是否达到推荐人群的研究。该研究评估了所有年龄段人群的使用情况，重点是65岁以上人群的使用情况，他们占所有COVID-19死亡人数的75%。为了最大限度地扩大公共卫生外展和受益，我们试图了解65岁以上至少有轻度COVID-19症状的个体使用和不使用OAV的原因。数据收集自美国人口普查家庭脉搏调查的第3.5阶段，在2022年的三个时间段：6月1日至13日，6月29日至7月11日和7月27日至8月8日。受访者（n = 12，299）年龄在18岁以上，在参与调查的最后4周内患有活动性或已消退的COVID-19。使用卡方独立性检验比较OAV摄取的人口统计学变量。进行逻辑回归以确定与接受OAV独立相关的参与者的特征。在那些年龄在65岁以上，至少有轻微症状的人之间进行了卡方检验，这些人支持不使用OAV的一些具体原因之一。利用率较低-所有受访者中有17.9%，50-64岁受访者中有20.5%，65岁及以上受访者中有33.9%接受了与指南一致的感染治疗。收入和性别没有差异。三个阶段的平均响应率为5.4%。不接受治疗的最常见原因包括症状轻微，不认为他们需要治疗，以及没有收到医疗保健提供者的建议。少数风险增加的美国居民已经获得了COVID-19的早期治疗，尽管可以免费获得。回应表明，努力提高患者和提供者的知识可以提高利用率，以减少未来的COVID-19住院。
This is the first study, to our knowledge, to assess uptake of oral antiviral treatment (OAV) for COVID-19 in the US and assess whether it is reaching recommended groups. The study evaluated uptake among persons of all ages, with emphasis on utilization among individuals ages 65 + who comprise 75% of all COVID-19 deaths. To maximize public health outreach and benefit, we sought to understand reasons for use and non-use of OAV among individuals 65 + with at least mild COVID-19 symptoms. Data were collected from phase 3.5 of the US Census Household Pulse Survey, during three 2022 time periods: June 1–13, June 29–July 11, and July 27–August 8. Respondents (n = 12,299) were ages 18 + with active or resolved COVID-19 within the last 4 weeks of their survey participation. Comparisons of demographic variables were made for OAV uptake using the chi-square test of independence. A logistic regression was conducted to identify characteristics of participants independently associated with receipt of an OAV. Comparisons were made with chi-square testing, between those ages 65 + with at least mild symptoms who endorsed one of a number of specific reasons for not using OAV. Utilization was low—17.9% of all respondents, 20.5% of respondents ages 50–64, and 33.9% of respondents 65 years and older received guideline-concordant treatment for their infection. Receipt did not differ by income or sex. The average response across the three phases was 5.4%. Most common reasons for not receiving treatment included having minimal symptoms, not thinking that they needed treatment, and not receiving a recommendation from their healthcare provider. A minority of increased-risk US residents have accessed early therapy for COVID-19 despite being made available without cost. Responses suggest that efforts to improve patient and provider knowledge could improve utilization to mitigate future COVID-19 hospitalizations.
影响因子：
5.5
作者：
Hsieh YL;Rak S;SteelFisher GK;Bauhoff S
通讯作者：
Bauhoff S